Navigation Links
AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
Date:6/23/2009

VIENNA, Austria, June 23 /PRNewswire/ -- MIG Fonds and AFFiRiS AG are this year's winners of the 2009 Venture Capital & Private Equity Award competition, hosted by the industry magazine Boerse-Express and Junge Industrie. The award recognised the long-standing association between the German venture fund and the Austrian biotechnology company as well as a euro 430 million deal between AFFiRiS and GSK Biologicals.

Last Tuesday MIG Fonds and AFFiRiS AG were awarded first place in the Venture Capital and Private Equity (VC/PE) awards by the Austrian industry magazine Boerse-Express.com and their co-sponsors Junge Industrie. The winners were chosen following a special selection process that combines the perspectives of the magazine's readers and selected experts, who evaluate corporate success stories from different perspectives. This year, an investment relationship that has been fruitful for both venture partners was recognised and the importance of VC financing for the start-up period of innovative businesses was thereby recognised.

Dr. Walter Schmidt, co-founder and CEO of AFFiRiS AG, commented that the VC/PE awards "have a very special significance for the capital investment market in Austria because they demonstrate the vital function of VC in the development of promising high-tech businesses. In our case, three years ago MIG Fonds started to invest a total of euro 11.5 million. Without this capital, our licensing deal with GSK Biologicals three years later would not have been possible. This deal is for up to euro 430 million in upfront and milestone payments for our Alzheimer's vaccines. MIG Fonds' decision to invest has therefore already been beneficial for everyone involved."

Based on the MIG Fonds investment, AFFiRiS AG was able to develop its AFFITOME(R) technology, which delivers innovative vaccines with very specific properties. The firm has already announced the development of candidates for therapeutic vaccines against Alzheimer's, Parkinson's and atherosclerosis - in other words, against diseases that have so far seemed unsuitable for treatment by vaccination, but that represent markets worth billions. Vaccine candidates for four further undisclosed chronic diseases are currently being developed by AFFiRiS AG.

Asked about the success story of AFFiRiS AG and the current award, Andreas Höfler of Alfred Wieder AG said: "We are very proud of this award. Good investment tends to not only promote advances in technology, but also to promote individuals and aims that are as visionary as they are clear. Our MIG fund managers also pay particular attention to ensuring that the target markets of our potential investees are of a sufficient size, and that the businesses we finance have the potential to become international market leaders. We recognised this potential in AFFiRiS three years ago - the first big pharma deal and the current award confirm our initial analysis."

About AFFiRiS AG (as at June 2009)

AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are used to treat Alzheimer's disease, atherosclerosis, Parkinson's disease and other diseases that urgently require a medical solution and that have considerable market potential. Alzheimer's disease is currently the principal indication and two potential products are in the final stages of clinical phase I studies. In October 2008, the company succeeded in gaining GlaxoSmithKline Biologicals as its licensing partner for the Alzheimer's vaccine. The contract anticipates milestone-dependent payments of up to euro 430 million. AFFiRiS currently employs 50 highly qualified staff and recently added an additional 1,100 sqm to its premises at the St. Marx campus in Vienna, Austria (http://www.affiris.com).

    Contact at AFFiRiS AG:

    Agnes Meyer
    Karl-Farkas-Gasse 22
    1030 Vienna
    Austria
    T +43-1-798-15-75 - 390
    E agnes.meyer@affiris.com

    Copy-editing & distribution:

    PR&D - Public Relations for Research & Education
    Campus Vienna Biocenter 2
    1030 Vienna
    Austria
    T +43-1-505-70-44
    E contact@prd.at



'/>"/>
SOURCE AFFiRiS AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
5. The next generation: nanomagnets could replace semiconductors
6. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
7. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
8. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
9. Campbell Alliance Named Best Place to Work by Triangle Business Journal
10. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
11. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016 The American Botanical Council ... of arnica ( Arnica montana ) through ABC,s ... HerbMedPro database, a comprehensive, interactive online ... clinical research data on the uses and health ... Naturopathica, a wellness company with healing arts ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the world’s largest privately-held contract pharmaceutical development and manufacturing organisation, today ... biopharma outsourcing company combining a leading CRO and the industry’s only Contract ...
(Date:12/6/2016)... ... December 06, 2016 , ... Discovering new clues to natural treatments that could ... happening in our brains. And searching for keys to our immune systems by studying ... with the 2017 Edith and Peter O’Donnell Awards by The Academy ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... plasma technology platforms, announced today that the company has engaged in a collaborative ... Development Agreement (MRDA) with the CSU Office of the Vice President for Research. ...
Breaking Biology Technology:
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
(Date:11/24/2016)... IRVINE, Calif. , Nov. 23, 2016 ... help endurance athletes and their trainers non-invasively measure ... Variability Index, Pulse Rate, and Respiration Rate in approximately ... Ember enables users easy and immediate access to key ... as part of a training regimen. ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):